33597857|t|Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway.
33597857|a|Background: The long-term administration of levodopa (L-dopa), the gold-standard treatment for Parkinson's disease (PD), is irreparably associated with L-dopa-induced dyskinesia (LID), which dramatically affects the quality of life of patients. However, the underlying molecular mechanisms of how LID exacerbates remain unknown. Neuroinflammation in the striatum plays an active role in LID. These findings prompt an investigation of non-neuronal mechanisms of LID. This study will examine the effects of systemic inflammation in the development and progression of LID. Methods: To evaluate the possible influence of systemic inflammation in the appearance of LID, the PD rats received an intraperitoneal (IP) injection of various concentrations of lipopolysaccharides (LPS, 1, 2, and 5 mg/kg) or saline. One day later, these PD rats started to receive daily treatment with L-dopa (6 mg/kg) along with benserazide (6 mg/kg) or saline for 21 days, and dyskinesia was evaluated at several time points. Moreover, the activation of microglia and astrocytes and the molecular changes in NR2B and mGLUR5 signaling pathways were measured. Results: We found that systemic inflammatory stimulation with LPS exacerbated the intensity of abnormal involuntary movements (AIMs) induced by L-dopa treatment in 6-hydroxydopamine (6-OHDA) lesioned rats. The LPS injection activated the gliocytes and increased the levels of proinflammatory cytokines in the striatum in LID rats. The PD rats that received the LPS injection showed the overexpression of p-NR2B and NR2B, as well as activated PKC/MEK/ERK and NF-kappaB signal pathways in response to the L-dopa administration. On the contrary, clodronate-encapsulated liposomes (Clo-lipo), which could suppress the inflammatory response induced by peripheral LPS injection, improved behavioral dysfunction, inhibited neuroinflammation, prevented NR2B overexpression, and decreased the phosphorylation of PKC/MEK/ERK and NF-kappaB signaling pathways. Conclusion: This study suggests that systemic inflammation, by exacerbating preexisting neuroinflammation and facilitating NR2B subunit activity, may play a crucial role in the development of LID. The administration of Clo-lipo restores the effects of LPS and decreases the susceptibility to LID in 6-OHDA lesioned rats.
33597857	9	21	Inflammation	Disease	MESH:D007249
33597857	54	62	Levodopa	Chemical	MESH:D007980
33597857	71	81	Dyskinesia	Disease	MESH:D004409
33597857	85	91	6-OHDA	Chemical	MESH:D016627
33597857	101	105	Rats	Species	10116
33597857	123	127	NR2B	Gene	24410
33597857	138	141	PKC	Gene	24681
33597857	146	149	ERK	Gene	24338
33597857	203	211	levodopa	Chemical	MESH:D007980
33597857	213	219	L-dopa	Chemical	MESH:D007980
33597857	254	273	Parkinson's disease	Disease	MESH:D010300
33597857	275	277	PD	Disease	MESH:D010300
33597857	311	317	L-dopa	Chemical	MESH:D007980
33597857	326	336	dyskinesia	Disease	MESH:D004409
33597857	338	341	LID	Disease	MESH:D004409
33597857	394	402	patients	Species	9606
33597857	456	459	LID	Disease	MESH:D004409
33597857	488	505	Neuroinflammation	Disease	MESH:D000090862
33597857	546	549	LID	Disease	MESH:D004409
33597857	620	623	LID	Disease	MESH:D004409
33597857	673	685	inflammation	Disease	MESH:D007249
33597857	724	727	LID	Disease	MESH:D004409
33597857	785	797	inflammation	Disease	MESH:D007249
33597857	819	822	LID	Disease	MESH:D004409
33597857	828	830	PD	Disease	MESH:D010300
33597857	831	835	rats	Species	10116
33597857	908	927	lipopolysaccharides	Chemical	MESH:D008070
33597857	929	932	LPS	Chemical	MESH:D008070
33597857	985	987	PD	Disease	MESH:D010300
33597857	988	992	rats	Species	10116
33597857	1033	1039	L-dopa	Chemical	MESH:D007980
33597857	1061	1072	benserazide	Chemical	MESH:D001545
33597857	1110	1120	dyskinesia	Disease	MESH:D004409
33597857	1241	1245	NR2B	Gene	24410
33597857	1250	1256	mGLUR5	Gene	24418
33597857	1323	1335	inflammatory	Disease	MESH:D007249
33597857	1353	1356	LPS	Chemical	MESH:D008070
33597857	1386	1416	abnormal involuntary movements	Disease	MESH:D004409
33597857	1418	1422	AIMs	Disease	MESH:D004409
33597857	1435	1441	L-dopa	Chemical	MESH:D007980
33597857	1455	1472	6-hydroxydopamine	Chemical	MESH:D016627
33597857	1474	1480	6-OHDA	Chemical	MESH:D016627
33597857	1491	1495	rats	Species	10116
33597857	1501	1504	LPS	Chemical	MESH:D008070
33597857	1612	1615	LID	Disease	MESH:D004409
33597857	1616	1620	rats	Species	10116
33597857	1626	1628	PD	Disease	MESH:D010300
33597857	1629	1633	rats	Species	10116
33597857	1652	1655	LPS	Chemical	MESH:D008070
33597857	1697	1701	NR2B	Gene	24410
33597857	1706	1710	NR2B	Gene	24410
33597857	1733	1736	PKC	Gene	24681
33597857	1741	1744	ERK	Gene	24338
33597857	1794	1800	L-dopa	Chemical	MESH:D007980
33597857	1834	1844	clodronate	Chemical	MESH:D004002
33597857	1905	1917	inflammatory	Disease	MESH:D007249
33597857	1949	1952	LPS	Chemical	MESH:D008070
33597857	1973	1995	behavioral dysfunction	Disease	MESH:D001523
33597857	2007	2024	neuroinflammation	Disease	MESH:D000090862
33597857	2036	2040	NR2B	Gene	24410
33597857	2094	2097	PKC	Gene	24681
33597857	2102	2105	ERK	Gene	24338
33597857	2186	2198	inflammation	Disease	MESH:D007249
33597857	2228	2245	neuroinflammation	Disease	MESH:D000090862
33597857	2263	2267	NR2B	Gene	24410
33597857	2332	2335	LID	Disease	MESH:D004409
33597857	2392	2395	LPS	Chemical	MESH:D008070
33597857	2432	2435	LID	Disease	MESH:D004409
33597857	2439	2445	6-OHDA	Chemical	MESH:D016627
33597857	2455	2459	rats	Species	10116
33597857	Association	MESH:D004409	24338
33597857	Negative_Correlation	MESH:D001545	MESH:D010300
33597857	Association	MESH:D007980	24681
33597857	Association	MESH:D010300	24410
33597857	Association	MESH:D016627	24338
33597857	Association	MESH:D007980	24338
33597857	Association	MESH:D007980	MESH:D007249
33597857	Association	MESH:D008070	MESH:D000090862
33597857	Association	MESH:D007249	24410
33597857	Association	MESH:D010300	24338
33597857	Positive_Correlation	MESH:D008070	MESH:D004409
33597857	Cotreatment	MESH:D001545	MESH:D007980
33597857	Positive_Correlation	MESH:D001545	MESH:D004409
33597857	Positive_Correlation	MESH:D007980	MESH:D008070
33597857	Positive_Correlation	MESH:D008070	24338
33597857	Positive_Correlation	MESH:D008070	MESH:D007249
33597857	Association	MESH:D010300	24681
33597857	Positive_Correlation	MESH:D007980	MESH:D004409
33597857	Association	MESH:D007249	24681
33597857	Association	MESH:D007249	24338
33597857	Association	MESH:D007980	24410
33597857	Association	MESH:D004409	24410
33597857	Association	MESH:D004409	24681
33597857	Negative_Correlation	MESH:D004002	MESH:D000090862
33597857	Negative_Correlation	MESH:D004002	MESH:D001523
33597857	Positive_Correlation	MESH:D008070	24410
33597857	Association	MESH:D004002	MESH:D008070
33597857	Negative_Correlation	MESH:D007980	MESH:D010300
33597857	Negative_Correlation	MESH:D008070	MESH:D010300
33597857	Positive_Correlation	MESH:D008070	24681
33597857	Negative_Correlation	MESH:D004002	MESH:D007249

